ArticleClinical optometry2026
Efficacy of Avastin in Improving Visual Acuity and Reducing Retinal Swelling in Patients with Diabetic Retinopathy at a Hospital in Gauteng (SA).
Article in Clinical optometry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Globally, diabetic retinopathy (DR) has been identified as the cause of blindness among adults with both Type 1 diabetes (T1DM) and Type 2 diabetes (T2DM). Purpose: The study aimed to investigate the efficacy of Avastin in improving visual acuity (VA) and reducing central foveal (CFT) and parafoveal thicknesses (PFT) in participants with DR. Patients and Methods: A cross-sectional observational study was conducted at a tertiary hospital in the Gauteng Province (South Africa). A total of 55 participants were included in the study, with VA's that were less than 0.5 LogMAR units and CFT's greater than 300 microns (µm). Measurements of VA's, CFT (µm), and PFT (µm) were conducted at baseline, after three and six months of receiving Avastin treatment. Numerical data were collected and analysed using IBM SPSS Version 28, and non-parametric tests were used to compare the means of the variables. Results: The mean VA improved from 1.00±0.71 LogMAR at baseline to 0.66±0.51 and 0.57±0.48 LogMAR at 3 and 6 months, respectively (p <0.001). The mean CFT improved from 441.22±142.35 µm at baseline to 355.58±129.38 µm and 308.40±137.60 µm at 3 and 6 months, respectively (p <0.001). The superior parafoveal thickness (SPFT) showed the highest decrease from a mean baseline of 379.04 µm to a mean baseline of 317.36 µm at 3 months. At 6 months, the decrease in the NPFT was statistically significant (p <0.025) in improving VA. Conclusion: Early administration of Avastin treatment in diabetic patients is effective in reducing the mean CFT, NPFT, and improving the mean VA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.